Bill > A02289

This bill enacts the Manufacturer Disclosure and Transparency Act, which requires pharmaceutical manufacturers to notify the New York State Attorney General about patent settlement agreements that potentially delay the introduction of generic medications. The bill defines key terms such as "patent settlement agreement," which includes any agreement related to resolving patent litigation between pharmaceutical manufacturers, and covers both traditional drugs and biological products. Specifically, pharmaceutical manufacturers must send the full text of any patent settlement agreement to the Attorney General within 30 days of its execution, and the Attorney General will then post these notices on their website in a searchable format that allows the public to review details about drugs, costs, diseases, and manufacturers. The bill includes a significant enforcement mechanism, imposing a fine of $10,000 per day for each day a manufacturer fails to submit the required notice. The purpose of the bill appears to be increasing transparency around pharmaceutical patent settlements that might delay generic drug competition, which can keep drug prices higher for consumers. The bill will take effect 180 days after becoming law, giving manufacturers time to prepare for the new reporting requirements.

Business and Industry

https://www.nysenate.gov/legislation/bills/2025/A2289